Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

UroGen Pharma (URGN) Return on Assets (2019 - 2025)

UroGen Pharma's Return on Assets history spans 7 years, with the latest figure at 0.8% for Q4 2025.

  • For Q4 2025, Return on Assets fell 36.0% year-over-year to 0.8%; the TTM value through Dec 2025 reached 0.8%, down 36.0%, while the annual FY2025 figure was 0.63%, 8.0% down from the prior year.
  • Return on Assets reached 0.8% in Q4 2025 per URGN's latest filing, up from 0.84% in the prior quarter.
  • In the past five years, Return on Assets ranged from a high of 0.4% in Q3 2024 to a low of 1.06% in Q1 2021.
  • Average Return on Assets over 5 years is 0.73%, with a median of 0.79% recorded in 2021.
  • Peak YoY movement for Return on Assets: skyrocketed 58bps in 2024, then plummeted -44bps in 2025.
  • A 5-year view of Return on Assets shows it stood at 0.87% in 2021, then grew by 5bps to 0.83% in 2022, then soared by 34bps to 0.55% in 2023, then grew by 21bps to 0.43% in 2024, then tumbled by -84bps to 0.8% in 2025.
  • Per Business Quant, the three most recent readings for URGN's Return on Assets are 0.8% (Q4 2025), 0.84% (Q3 2025), and 0.68% (Q2 2025).